ACE2 and COVID-19: The RBD mediates virus attachment to the angiotensin converting enzyme 2 (ACE2) receptor on target cells and is the principal target of neutralizing antibodies that contribute to protection against SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19).